Stromal expression of beta;-arrestin-1 predicts clinical outcome and tamoxifen response in breast cancer

Journal of Molecular Diagnostics

Volumn 13, Issue 3, 2011, Pages 340-351

  Lundgren, Katja ^a,b   Tobin, Nicholas P ^b   Lehn, Sophie ^a,b   Stal, Olle ^c   Lisa, Rydén ^a   Jirström, Karin ^a   Landberg, Göran ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN 1; TAMOXIFEN;

ADULT; AGED; ARRB1 GENE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER PATIENT; CANCER SURVIVAL; CCND1 GENE; CELL LINE; CELL MIGRATION; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GENE; GENE AMPLIFICATION; GENE DELETION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREDICTION; PROTEIN EXPRESSION; STROMA CELL; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 79955009165     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2011.01.009     Document Type: Article

References (59)

1. Lefkowitz RJ, Whalen EJ: beta-arrestins: traffic cops of cell signaling.Curr Opin Cell Biol 2004, 16:162-168 (Pubitemid 38757292)
2. Shenoy SK, Lefkowitz RJ: Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. Biochem J 2003, 375:503-515 (Pubitemid 37433499)
3. Kang J, Shi Y, Xiang B, Qu B, Su W, Zhu M, Zhang M, Bao G, Wang F, Zhang X, Yang R, Fan F, Chen X, Pei G, Ma L: A nuclear function of beta-arrestin1 in GPCR signaling: regulation of histone acetylation and gene transcription [Erratum appeared in Cell 2006, 124:645]. Cell 2005, 123:833-847
4. Ma L, Pei G: Beta-arrestin signaling and regulation of transcription. J Cell Sci 2007, 120:213-218
5. Lefkowitz RJ, Shenoy SK: Transduction of receptor signals by betaarrestins. Science 2005, 308:512-517
6. Zou L, Yang R, Chai J, Pei G: Rapid xenograft tumor progression in beta-arrestin1 transgenic mice due to enhanced tumor angiogenesis. FASEB J 2008, 22:355-364 (Pubitemid 351227345)
7. Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN: Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci USA 2006, 103:1492-1497 (Pubitemid 43191193)
8. Ge L, Shenoy SK, Lefkowitz RJ, DeFea K: Constitutive proteaseactivated receptor-2-mediated migration of MDA MB-231 breast cancer cells requires both beta-arrestin-1 and -2. J Biol Chem 2004, 279:55419-55424 (Pubitemid 40066542)
9. Li TT, Alemayehu M, Aziziyeh AI, Pape C, Pampillo M, Postovit LM, Mills GB, Babwah AV, Bhattacharya M: Beta-arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells. Mol Cancer Res 2009, 7:1064-1077
10. Zhao M, Zhou G, Zhang Y, Chen T, Sun X, Stuart C, Hanley G, Li J, Zhang J, Yin D: Beta-arrestin2 inhibits opioid-induced breast cancer cell death through Akt and caspase-8 pathways. Neoplasma 2009, 56:108-113
11. Calabrese G, Sallese M, Stornaiuolo A, Morizio E, Palka G, De Blasi A: Assignment of the beta-arrestin 1 gene (ARRB1) to human chromosome 11q13. Genomics 1994, 24:169-171 (Pubitemid 24368760)
12. Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, Lin F, Kawakatsu H, Owada K, Luttrell DK, Caron MG, Lefkowitz RJ: Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 1999, 283:655-661
13. Bièche I, Olivi M, Noguès C, Vidaud M, Lidereau R: Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br J Cancer 2002, 86:580-586 (Pubitemid 34185096)
14. Kenny FS, Hui R, Musgrove EA, Gee JM, Blamey RW, Nicholson RI, Sutherland RL, Robertson JF: Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res 1999, 5:2069-2076 (Pubitemid 29399260)
15. Jirström K, Stendahl M, Rydén L, Kronblad A, Bendahl PO, Stal O, Landberg G: Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res 2005, 65:8009-8016 (Pubitemid 41297281)
16. Schraml P, Schwerdtfeger G, Burkhalter F, Raggi A, Schmidt D, Ruffalo T, King W, Wilber K, Mihatsch MJ, Moch H: Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma. Am J Pathol 2003, 163:985-992 (Pubitemid 37040134)
17. Holm C, Rayala S, Jirström K, Stal O, Kumar R, Landberg G: Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst 2006, 98:671-680 (Pubitemid 43821785)
18. Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL: Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 2003, 78:323-335 (Pubitemid 36543212)
19. Shuster MI, Han L, Le Beau MM, Davis E, Sawicki M, Lese CM, Park NH, Colicelli J, Gollin SM: A consistent pattern of RIN1 rearrangements in oral squamous cell carcinoma cell lines supports a breakage- fusion-bridge cycle model for 11q13 amplification. Genes Chromosomes Cancer 2000, 28:153-163 (Pubitemid 30246993)
20. Lundgren K, Holm K, Nordenskjöld B, Borg A, Landberg G: Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer. Breast Cancer Res 2008, 10:R81
21. Nilsson P, Paavilainen L, Larsson K, Odling J, Sundberg M, Andersson AC, Kampf C, Persson A, Al-Khalili Szigyarto C, Ottosson J, Björling E, Hober S, Wernérus H, Wester K, Pontén F, Uhlén M: Towards a human proteome atlas: high-throughput generation of mono-specific antibodies for tissue profiling. Proteomics 2005, 5:4327-4337 (Pubitemid 41739911)
22. Uhlén M, Björling E, Agaton C, Szigyarto CA, Amini B, Andersen E, et al: A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 2005, 4:1920-1932 (Pubitemid 41830186)
23. Andersson AC, Strömberg S, Bäckvall H, Kampf C, Uhlén M, Wester K, Pontén F: Analysis of protein expression in cell microarrays: a tool for antibody-based proteomics. J Histochem Cytochem 2006, 54: 1413-1423 (Pubitemid 44788826)
24. Pontén F, Jirström K, Uhlén M: The Human Protein Atlas-a tool for pathology. J Pathol 2008, 216:387-393
25. Jögi A, Brennan Ryd́n, DJ L, Magnusson K, Fernö M, Stal O, Borgquist S, Uhĺn M, Landberg G, Pahlman S, Pont́n F, Jirström K: Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer. Mod Pathol 2009, 22:1564-1574
26. Björling E, Lindskog C, Oksvold P, Linń J, Kampf C, Hober S, Uhĺn M, Pont́n F: A Web-based tool for in silico biomarker discovery based on tissue-specific protein profiles in normal and cancer tissues. Mol Cell Proteomics 2008, 7:825-844 (Pubitemid 351737085)
27. Lundgren K, Nordenskjöld B, Landberg G: Hypoxia, Snail and incomplete epithelial-mesenchymal transition in breast cancer. Br J Cancer 2009, 101:1769-1781
28. Song X, Raman D, Gurevich EV, Vishnivetskiy SA, Gurevich VV: Visual and both non-visual arrestins in their "inactive" conformation bind JNK3 and Mdm2 and relocalize them from the nucleus to the cytoplasm. J Biol Chem 2006, 281:21491-21499 (Pubitemid 44115487)
29. Rexhepaj E, Brennan DJ, Holloway P, Kay EW, McCann AH, Landberg G, Duffy MJ, Jirström K, Gallagher WM: Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. Breast Cancer Res 2008, 10:R89
30. Helczynska K, Larsson AM, Holmquist Mengelbier L, Bridges E, Fredlund E, Borgquist S, Landberg G, Pahlman S, Jirström K: Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res 2008, 68:9212-9220
31. Ryd́n L, Jönsson PE, Chebil G, Dufmats M, Fernö M, Jirström K, Källström AC, Landberg G, Stal O, Thorstenson S, Nordenskjöld B; South Swedish Breast Cancer Group; South-East Swedish Breast Cancer Group: Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with longterm follow-up. Eur J Cancer 2005, 41:256-264 (Pubitemid 40136540)
32. Jirström K, Ryd́n L, Anagnostaki L, Nordenskjöld B, Stal O, Thorstenson S, Chebil G, Jönsson PE, Fernö M, Landberg G: Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial. J Clin Pathol 2005, 58:1135-1142 (Pubitemid 41566455)
33. Ryd̀n L, Landberg G, Stal O, Nordenskjöld B, Fernö M, Bendahl PO: HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information. Breast Cancer Res Treat 2008, 109:351-357 (Pubitemid 351644858)
34. Kronblad A, Jirström K, Ryd̀n L, Nordenskjöld B, Landberg G: Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response. Int J Cancer 2006, 118:2609-2616
35. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics: Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005, 97:1180-1184
36. Elenbaas B, Weinberg RA: Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res 2001, 264:169-184 (Pubitemid 32989090)
37. Rhodes LV, Muir SE, Elliott S, Guillot LM, Antoon JW, Penfornis P, Tilghman SL, Salvo VA, Fonseca JP, Lacey MR, Beckman BS, McLachlan JA, Rowan BG, Pochampally R, Burow ME: Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Res Treat 2010, 121:293-300
38. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M: Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008, 14:518-527 (Pubitemid 351655218)
39. Polyak K, Haviv I, Campbell IG: Co-evolution of tumor cells and their microenvironment. Trends Genet 2009, 25:30-38
40. Mueller MM, Fusenig NE: Friends or foes- bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004, 4:839-849 (Pubitemid 39472951)
41. Werner S, Grose R: Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003, 83:835-870 (Pubitemid 36828927)
42. Sappino AP, Skalli O, Jackson B, Schürch W, Gabbiani G: Smoothmuscle differentiation in stromal cells of malignant and non-malignant breast tissues. Int J Cancer 1988, 41:707-712
43. Chauhan H, Abraham A, Phillips JR, Pringle JH, Walker RA, Jones JL: There is more than one kind of myofibroblast: analysis of CD34 expression in benign, in situ, and invasive breast lesions. J Clin Pathol 2003, 56:271-276 (Pubitemid 36459796)
44. Cunha GR, Hayward SW, Wang YZ, Ricke WA: Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer 2003, 107:1-10 (Pubitemid 37100079)
45. Weber F, Xu Y, Zhang L, Patocs A, Shen L, Platzer P, Eng C: Microenvironmental genomic alterations and clinicopathological behavior in head and neck squamous cell carcinoma. JAMA 2007, 297:187-195 (Pubitemid 46089735)
46. Harris AL: Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38-47 (Pubitemid 37328806)
47. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874
48. Hattar R, Maller O, McDaniel S, Hansen KC, Hedman KJ, Lyons TR, Lucia S, Wilson RS Jr, Schedin P: Tamoxifen induces pleiotrophic changes in mammary stroma resulting in extracellular matrix that suppresses transformed phenotypes. Breast Cancer Res 2009, 11:R5
49. Shekhar MP, Santner S, Carolin KA, Tait L: Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity. Am J Pathol 2007, 170:1546-1560 (Pubitemid 47339300)
50. Gupta PB, Proia D, Cingoz O, Weremowicz J, Naber SP, Weinberg RA, Kuperwasser C: Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res 2007, 67:2062-2071 (Pubitemid 46424224)
51. Paz K, Hadari YR: Targeted therapy of the insulin-like growth factor-1 receptor in cancer. Comb Chem High Throughput Screen 2008, 11:62-69
52. Girnita L, Shenoy SK, Sehat B, Vasilcanu R, Girnita A, Lefkowitz RJ, Larsson O: {beta}-Arrestin is crucial for ubiquitination and downregulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase. J Biol Chem 2005, 280:24412-24419 (Pubitemid 40934525)
53. Girnita L, Shenoy SK, Sehat B, Vasilcanu R, Vasilcanu D, Girnita A, Lefkowitz RJ, Larsson O: Beta-arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression. J Biol Chem 2007, 282:11329-11338 (Pubitemid 47100796)
54. Sloan EK, Ciocca DR, Pouliot N, Natoli A, Restall C, Henderson MA, Fanelli MA, Cuello-Carrión FD, Gago FE, Anderson RL: Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol 2009, 174:2035-2043
55. Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, Kleer CG, Brody JR, Lisanti MP: An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 2009, 174:2023-2034
56. Kubale V, Abramovíc Z, Pogacnik A, Heding A, Sentjurc M, Vrecl M: Evidence for a role of caveolin-1 in neurokinin-1 receptor plasmamembrane localization, efficient signaling, and interaction with betaarrestin 2. Cell Tissue Res 2007, 330:231-245 (Pubitemid 47512587)
57. Paulsson J, Sjöblom T, Micke P, Pont̀n F, Landberg G, Heldin CH, Bergh J, Brennan DJ, Jirström K, Ostman A: Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 2009, 175:334-341
58. Hui R, Campbell DH, Lee CS, McCaul K, Horsfall DJ, Musgrove EA, Daly RJ, Seshadri R, Sutherland RL: EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer. Oncogene 1997, 15:1617-1623 (Pubitemid 27464656)
59. Chunder N, Mandal S, Roy A, Roychoudhury S, Panda CK: Analysis of different deleted regions in chromosome 11 and their interrelations in early- and late-onset breast tumors: association with cyclin D1 amplification and survival. Diagn Mol Pathol 2004, 13:172-182 (Pubitemid 39121744)